Skip to main content
Home
Loading...
Menu social network
  • LinkedIn
  • Facebook
  • X
  • Youtube

Menu top

  • Assistance

User account menu

  • Log in
Home

Main navigation

  • Home
  • Programme
Menu Login
Close

Main navigation mobile

  • Home
  • Programme

Menu top

  • Assistance
Menu social network
  • LinkedIn
  • Facebook
  • X
  • Youtube
Filters
Filters Close
Poster topics
Poster available until
  • Until platform closure (22)
Poster categories
  • Thematic Poster Session (26)
keywords
Session Reference
  • L-TPS01 (10)
  • L-TPS02 (13)
  • L-TPS03 (5)
  • L-TPS04 (12)
  • L-TPS05 (10)
  • L-TPS06 (7)
  • L-TPS07 (8)
  • L-TPS08 (7)
  • L-TPS09 (10)
  • L-TPS10 (10)
  • L-TPS11 (10)
  • L-TPS12 (8)
  • L-TPS13 (8)
  • L-TPS14 (11)
  • L-TPS15 (6)
  • L-TPS16 (7)
  • L-TPS17 (9)
  • L-TPS18 (9)
  • L-TPS19 (6)
  • L-TPS20 (7)
  • L-TPS21 (7)
  • L-TPS22 (9)
  • L-TPS23 (13)
  • L-TPS24 (10)
  • L-TPS25 (2)
  • TPS01 (9)
  • TPS02 (10)
  • TPS03 (6)
  • TPS04 (6)
  • TPS05 (10)
  • TPS06 (10)
  • x TPS07 (6)
  • TPS08 (12)
  • TPS09 (12)
  • TPS10 (5)
  • TPS11 (6)
  • TPS12 (6)
  • TPS13 (10)
  • TPS14 (6)
  • TPS15 (4)
  • TPS16 (9)
  • TPS17 (8)
  • TPS18 (9)
  • TPS19 (9)
  • TPS20 (8)
  • TPS21 (10)
  • TPS22 (7)
  • x TPS23 (8)
  • TPS24 (8)
  • TPS25 (5)
  • TPS26 (9)
  • TPS27 (12)
  • TPS28 (4)
  • TPS29 (5)
  • TPS30 (10)
  • TPS31 (5)
  • TPS32 (12)
  • x TPS33 (12)
  • TPS34 (10)
  • TPS35 (7)
  • TPS36 (8)
  • TPS37 (10)
  • TPS38 (8)
  • TPS39 (10)
  • TPS40 (4)
  • TPS41 (10)
  • TPS42 (12)
  • TPS43 (12)
  • TPS44 (9)
  • TPS45 (10)
  • TPS46 (6)
  • TPS47 (11)
  • TPS48 (7)
  • TPS49 (10)
  • TPS50 (5)
  • TPS51 (2)
  • TPS52 (8)
  • TPS53 (6)
  • TPS54 (8)
  • TPS55 (7)
  • TPS56 (10)
  • TPS57 (4)
  • TPS58 (4)
  • TPS59 (12)
  • TPS60 (9)
  • TPS61 (7)
  • TPS62 (10)
  • TPS63 (10)
  • TPS64 (12)
  • TPS65 (13)
  • TPS66 (7)
  • TPS67 (10)
  • TPS68 (5)
  • TPS69 (11)
  • TPS70 (8)
  • TPS71 (8)
  • TPS72 (10)
  • TPS73 (9)
  • TPS74 (8)
  • TPS75 (7)
  • TPS76 (9)
  • TPS77 (6)
  • TPS78 (12)
  • TPS79 (2)
  • TPS80 (8)
  • TPS81 (6)
  • TPS82 (5)
  • TPS83 (4)
  • TPS84 (7)
  • TPS85 (8)
  • TPS86 (11)
  • TPS87 (7)
  • TPS88 (8)
  • TPS89 (4)
  • TPS90 (4)
  • TPS91 (3)
26 results
Thumbnail

D1.123 - Visualization of neutrophil extracellular traps (NETs) and autoantibodies targeting myeloperoxidase (MPO) and neutrophil elastase (NE) in sputum by confocal microscopy

Thumbnail

D1.124 - Changes in respiratory infections patterns in Patients with Severe Asthma and a High burden of comorbidities treated with tezepelumab: interim analysis results of the T-ROSS II study

Thumbnail

D1.126 - Therapeutic Splenic Ultrasound Insonation as a Modulator of Pro-atherogenic and Pro-asthmatic Immune Inflammation: A Preclinical Study Design

Thumbnail

D1.128 - Use of Tezepelumab in four Patients with Allergic Bronchopulmonary Aspergillosis and severe uncontrolled Asthma: A Case Series

Thumbnail

D1.130 - Immune markers after one year treatment with benralizumab in severe eosinophilic asthma

Thumbnail

D1.131 - Unconventional Group 2 Innate Lymphoid Cells Expressing C-Kit and IL-17A are Increased in Sputum from Severe Asthma with Mixed Granulocytic Airway Inflammation

Thumbnail

D1.437 - A Decade of Research on Janus Kinase Inhibitors in Atopic Dermatitis: A Global Bibliometric Analysis (2015–2024)

Thumbnail

D1.438 - Dupilumab for Moderate-to-Severe Atopic Dermatitis in Children and Adolescents: Real-Life Assessment of Efficacy and Safety

Thumbnail

D1.442 - Design and Preclinical Development of a Bispecific Antibody Targeting IL11 and TL1A

Thumbnail

D1.443 - Preclinical Development of a Dual LIGHT/TL1A Bispecific Antibody

Thumbnail

D1.447 - Comparison of Disease Duration, Remission, and Other Disease-Related Parameters with the Duration of Omalizumab Treatment in Patients with Chronic Spontaneous Urticaria

Thumbnail

D1.448 - Long-Term Efficacy and Stability of Lebrikizumab in Treating Face/Head and Neck Involvement in Patients with Moderate-to-Severe Atopic Dermatitis

Thumbnail

D1.449 - A Phase 2, Open-Label Extension Study to Evaluate the Long-Term Safety and Efficacy of Briquilimab in Adults with Chronic Urticaria (Trial in Progress)

Thumbnail

D1.439 - Urticaria Voices: Physician-reported perspectives of chronic urticaria care and its treatment in China (UV in China)

Thumbnail

D2.44 - Subjective assessment of sleep quality in adult patients with hereditary angioedema

Thumbnail

D2.47 - Unmasking Melkersson-Rosenthal Syndrome: Diagnostic Challenges in a Patinent Pressenting With Angioedema

Thumbnail

D2.43 - Hereditary Angioedema Can Hit at Any Age: A Case Report in Egypt

Thumbnail

D2.45 - Fixed Drug Eruption Due to Fenofibrate Hypersensitivity

Thumbnail

D2.46 - Patient with the overlap of Hereditary angioedema and Chronic spontaneous urticaria

Thumbnail

D2.48 - When Treatment Becomes the Cause: Allergic Contact Dermatitis to Topical Corticosteroids

Pagination

  • Current page 1
  • Page 2
  • Next page Next
  • Last page Last
Download the app
The congress at your fingertips

Available on

App Store Google Play
QR Code Download
Mobile App Schedule page
Mobile App Home page
Menu social network
  • LinkedIn
  • Facebook
  • X
  • Youtube
© 2026 EAACI
Made with   by CYIM